Tour hospital, "tariffs", moonlake: three: This article explores the topic in depth.
Nevertheless,
Tour hospital, "tariffs", moonlake: three:
1. Nevertheless, The Tower Hospital reorganized to find black figures from 2026
Last year. Furthermore, for the first time in its history, the Tour hospital recorded a loss, amounting to 5 million francs for a turnover of around 250 million. Moreover, This situation results from an prolonged conflict with several health insurers. However, which, between May 2024 and June 2025, temporarily ceased to reimburse the services invoiced by the doctors and the institution, and covered by the additional police.
The LATSIS family controlled, however, continued to welcome part of the patients concerned at its expense. Consequently, “It was an assumed decision to preserve the continuity of care for our patients. For example, support our doctors,” claims the chairman of the board of directors, Jenny Paizi.
2. “Donald Trump is serious about the prices. because they will allow him to finance his budget”
Monday, tour hospital, “tariffs”, moonlake: three Donald Trump reported letters sent to fourteen countries, mainly in Asia, informing them of the entry into force at 1is August importation of import taxes that can climb up to 40%. If uncertainty remains important, Asian markets have reacted in moderation to these announcements, pending negotiations. For their part. Switzerland and the countries of the European Union are still waiting to know the fate reserved for them by the American president. What are the consequences on markets and currencies? Interview with Samy Chaar, chief economist and Swiss IOC at Lombard Odier.
3. Moonlake. the Swiss biotech which has raised nearly a billion to treat illnesses so far without cure
This is an article of Financial Times Who aroused a strong reaction from the markets a month ago: the American pharmaceutical giant Merck wanted to buy the Swiss start-up Moonlake Immunotherapeutics for more than $ 3 billion. Result: the course of tour hospital, “tariffs”, moonlake: three the Biotech listed at the NASDAQ flew off (+30% in one day). investors betting on a potential acquisition of the start-up which targets inflammatory diseases.
If he does not wish to comment on this information. Matthias Bodenstedt, CFO and co -founder of Moonlake, returns to the deployment strategy of the single molecule at the company’s portfolio, on several therapeutic fronts. He also specifies the calendar of a nearby first marketing. returns to the loan of $ 500 million contracted at the end of March and announces the upcoming installation of an antenna in the United States, while its activities are already distributed between Zug, Cambridge and Porto. Interview.
Tour hospital, "tariffs", moonlake: three – Tour hospital, "tariffs", moonlake: three
Further reading: Releases, closures and anger of employees: around a high tension in banks – Prime Day: Amazon takes a slap – Bringing French debt to 110 % of GDP would require an effort of 110 billion euros – Dieselgate: a third aggravated deception trial required against Renault, after Volkswagen and Peugeot-Citroën: News – Sun Chemical: two days of strike for a better social plan.
